Sangamo BioSciences Stock News

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price closed higher on Monday, February 07, jumping 2.88% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Sangamo Therapeutics (SGMO) said preliminary data from a phase 1/2 study, dubbed STAAR, of its gene therapy isaralgagene civaparvovec (ST-920) continued to be well tolerated in…

Sangamo Therapeutics Inc (NASDAQ: SGMO ) announced updated preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), Fabry disease gene therapy candidate. Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide (Gb3), in the body''s cells. It is caused by mutations in the galactosidase alpha gene ( GLA ), resulting in deficient alpha-galactosidase A (α-Gal A) enzyme activity, necessary for metabolizing … Full story available on Benzinga.com

Sangamo Therapeutics Inc SGMO announced updated preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), Fabry disease gene therapy candidate. Get the Inside Access

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. These latest data show that, as of the November 9, 2021 cutoff date, the investigational treatment continued to be well tolerated and that the four longest treated patients conti

Sangamo Therapeutics (SGMO) falls 8% premarket following an announcement that Sanofi (SNY) will be transitioning its rights and obligations related to SAR445136, a zinc finger

(RTTNews) - Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF, SNY) will be transitioning its rights and obligations related to SAR445136 back to Sangamo over the first half of 2022. SAR445136 is a zinc finger nuclease gene-edited cell therapy candidate in development by Sangamo

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright B

SG Americas Securities LLC lifted its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 7.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 667,781 shares of the biopharmaceutical companys stock after purchasing an additional 48,356 shares during the period. SG Americas Securities LLC owned 0.46% of []

Banque Cantonale Vaudoise lessened its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 6.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 36,537 shares of the biopharmaceutical company’s stock after selling 2,713 shares during the period. Banque Cantonale Vaudoise’s holdings in Sangamo Therapeutics were worth $329,000 […]

Sangamo Therapeutics Inc. (NASDAQ:SGMO) has a beta value of 1.52 and has seen 1.0 million shares traded in the last trading session. The company, currently valued at $1.13B, closed the last trade at $8.28 per share which meant it gained $0.03 on the day or 0.36% during that session. The SGMO stock price is -134.66% Weak Fundamental Momentum Sinks Sangamo Therapeutics Inc. Read More »

The trading price of Sangamo Therapeutics Inc. (NASDAQ:SGMO) closed lower on Monday, December 13, closing at $7.29, -5.69% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Sangamo Therapeutics Inc. (SGMO) announced updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two years fol